KRT33B

Across TCGA pan-cancer cohorts, KRT33B mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated KRT33B data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher KRT33B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated KRT33B expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

HNSC, LUAD, and GBM are the cancer types where KRT33B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	IV	0.690	0.947	.002	30	view →
LUAD	OS	Quartile	II,III,IV	1.000	0.440	.016	12	view →
GBM	OS	Tertile	All	0.577	0.225	.009	6	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	6	view →
OV	DFS	Median	All	1.000	0.851	.029	4	view →
LSCC	DFS	Tertile	III,IV	0.879	0.428	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

KRT33B–HNSC (OS)

Open the HNSC breakdown →